Accent Therapeutics
Accent Therapeutics, based in Lexington, MA, develops small molecule therapeutics targeting RNA-modifying proteins for cancer treatment. The company has a partnership with AstraZeneca and has raised $75 million in Series C financing.
Location and Address
Accent Therapeutics is located at 1050 Waltham St., Suite 201, Lexington, MA 02421. This location houses their main offices and research facilities where they develop innovative cancer treatments.
Cancer Treatment Therapeutics
Accent Therapeutics develops small molecule therapeutics targeting RNA-modifying proteins (RMPs) for cancer treatment. Their pipeline includes both first-in-class and best-in-class programs aimed at addressing significant unmet medical needs in cancer therapy. Their lead programs target DHX9 and KIF18A, focusing on cancers with high unmet clinical needs.
Green Lab Certification
Accent Therapeutics has achieved 'Green Lab' status under the My Green Lab Certification Program. This certification reflects the company's commitment to reducing the environmental impact of their research and laboratory practices.
Partnership with AstraZeneca
Accent Therapeutics has formed a partnership with AstraZeneca to discover and develop novel cancer therapeutics targeting RNA-modifying proteins. This collaboration aims to leverage the strengths of both companies in the field of precision oncology.
Series C Financing and Pipeline Progress
Accent Therapeutics secured $75 million in Series C financing to advance their small molecule precision cancer therapies. They presented data supporting their two lead programs at the AACR 2024 Annual Meeting, showcasing their continued progress and innovation in cancer treatment.